 Pfizer Inc. PFE, -0.21 and Germany-based partner BioNTech SE BNTX, 2.64 said new data from a Phase 23 trial showed that the booster for companies omicron BA.4BA.5-adapted bivalent COVID-19 vaccine demonstrated a robust neutralizing immune response after one month. The companies said immune responses for those getting the booster were substantially higher than for those who only received the original COVID-19 vaccine, with similar safety and tolerability profiles. 